Insulin resistance impairs nigrostriatal dopamine function
about
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideDietary factors in the etiology of Parkinson's disease.PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.Prolonged high fat diet reduces dopamine reuptake without altering DAT gene expression.Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humansEating high fat chow decreases dopamine clearance in adolescent and adult male rats but selectively enhances the locomotor stimulating effects of cocaine in adolescents.You are what you eat: influence of type and amount of food consumed on central dopamine systems and the behavioral effects of direct- and indirect-acting dopamine receptor agonists.The spontaneously hypertensive and Wistar Kyoto rat models of ADHD exhibit sub-regional differences in dopamine release and uptake in the striatum and nucleus accumbensA high fat diet alters metabolic and bioenergetic function in the brain: A magnetic resonance spectroscopy study.Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylaseAttenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetesDietary fat intake, pesticide use, and Parkinson's disease.Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies.Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals rewardA novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.High-Fat-Diet-Induced Deficits in Dopamine Terminal Function Are Reversed by Restoring Insulin Signaling.PINK1 deficiency in β-cells increases basal insulin secretion and improves glucose tolerance in mice.High fat/carbohydrate ratio but not total energy intake induces lower striatal dopamine D2/3 receptor availability in diet-induced obesity.High fructose corn syrup induces metabolic dysregulation and altered dopamine signaling in the absence of obesity.Intermittent Fasting Applied in Combination with Rotenone Treatment Exacerbates Dopamine Neurons Degeneration in Mice.Iron influences on the Gut-Brain axis and development of type 2 diabetes.The Carnitine Palmitoyl Transferase (CPT) System and Possible Relevance for Neuropsychiatric and Neurological Conditions.To Do or Not to Do: Dopamine, Affordability and the Economics of Opportunity.Effect of chronic consumption of blackberry extract on high-fat induced obesity in rats and its correlation with metabolic and brain outcomes.The Therapeutic Potential of Metformin in Neurodegenerative Diseases
P2860
Q28067465-A0973D74-F266-4BCF-85C2-D346B3C6AD28Q28081671-68B3B800-D472-4294-84FD-B2C32E868931Q28085390-F1DE77F5-C834-4A11-87F5-A30E84ABCDFCQ33960389-878967FB-1C61-4376-A020-5807F4B3A8BCQ34629482-E1FC3D1A-F2D6-4D29-8C67-96F24E6F5E45Q35965889-BF190B79-E517-40ED-82D4-1AECDD421179Q35965902-FDE70A60-58C8-49B2-81FB-B49B176763AEQ36045250-A6927138-6CC5-4BEC-BA93-8592068CE84CQ36361756-041AF4B9-5903-43C8-AA4A-9142515E0264Q36989464-A9D4BFB9-C19E-45F7-A9D6-87BC422FA490Q37212345-A1C36240-7DF8-4AF9-B895-9E682D08B9DCQ37578164-A04D9806-EDEB-4FCA-BF35-91047B7E4722Q37606627-CB9496F1-974F-40FC-B373-0BF4634A2C3DQ37962621-40E19C62-BDB2-45FE-AC55-02D2160532DDQ38039489-522471E2-809E-4383-80A8-376153ED61A4Q38075505-566EFAA0-0983-4F30-A41B-23C7BDE885C8Q38197368-C2AC3F54-BE4C-480E-B059-5BDFC23DB5E6Q38295730-1457E953-1D07-48C3-8A1B-4F8C9D18F8AAQ38660754-86E811D7-8ADF-4D67-9035-2CCE31FF6A2FQ38668948-B66B4380-EFDE-44AF-9686-2D45D3841B58Q39102392-7261788E-7019-4D60-84A2-C648C4740B6EQ40214351-4F01950D-1EA2-41F9-9842-59B0833A1774Q43890136-876CD27E-46BC-41EE-9D83-572A6BBB87B7Q47233946-0BA41C96-01D1-4B7C-A498-5BF94E1E8B1FQ47827804-0669DD5A-CE6E-4486-BE0C-AA54B03E2EADQ48121643-16EFCE48-5E70-4019-8CEB-C224B6A842D6Q48146067-65A688C1-2111-4194-8309-C7D00A300189Q50300994-5A2F07C9-33F8-4038-BC76-7A01F7A28DDBQ52148008-531EE2BF-C6E9-490F-8355-D1CB05C89F39Q57175337-4C117D13-2656-4A28-90A0-BF9E92E8CABC
P2860
Insulin resistance impairs nigrostriatal dopamine function
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Insulin resistance impairs nigrostriatal dopamine function
@ast
Insulin resistance impairs nigrostriatal dopamine function
@en
type
label
Insulin resistance impairs nigrostriatal dopamine function
@ast
Insulin resistance impairs nigrostriatal dopamine function
@en
prefLabel
Insulin resistance impairs nigrostriatal dopamine function
@ast
Insulin resistance impairs nigrostriatal dopamine function
@en
P2093
P2860
P1476
Insulin resistance impairs nigrostriatal dopamine function
@en
P2093
B K Gorres
G A Gerhardt
G L Bomhoff
J A Stanford
J K Morris
P C Geiger
P2860
P304
P356
10.1016/J.EXPNEUROL.2011.06.005
P407
P577
2011-06-15T00:00:00Z